![](https://lifescicommunications.com/wp-content/uploads/2018/09/xconomy-logo-may2017-rgb-300x54.png)
Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug
Arrowhead Pharmaceuticals on Thursday made public select initial data from an early-stage clinical study of a hepatitis B drug it’s developing, sending the company’s stock price (NASDAQ: ARWR) to a four-year high. Arrowhead shared data from a study aimed at evaluating the safety and tolerability of a drug candidate it’s developing to treat chronic hepatitis B virus (HBV). An estimated 257 million people worldwide are living with HBV infection, which can lead to cirrhosis and liver cancer, according to the World Health Organization.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/a3912338358eaf54c75fd812c3f44f3f-300x57.jpg)
Arrowhead’s Third-Generation RNAi Shows Initial Efficacy Against HBV
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained $5.29 (38%) to $19.39 Thursday after reporting initial data showing that monthly doses of its third-generation RNAi therapy ARO-HBV reduced circulating HBV surface antigen (HBsAg) in a broad population of patients with chronic HBV infection. The biotech added $465 million in market cap on the data.
![](https://lifescicommunications.com/wp-content/uploads/2018/07/IBD_Logo-300x202.png)
This Biotech Broke Out Bullishly On Its Experimental Hepatitis B Drug
Arrowhead Pharmaceuticals (ARWR) broke out in bullish fashion Thursday on strong data for a study of its hepatitis B treatment. On the stock market today Arrowhead stock rocketed 37.5%, to 19.39, after earlier flying as much as 58.8% in high volume. Shares touched a four-year high and broke out of a consolidation with a buy point at 17.60.
![](https://lifescicommunications.com/wp-content/uploads/2018/06/Motley-Fool-logo-1-300x56.png)
Here’s Why ProQR Therapeutics N.V. Is Skyrocketing Today
After reporting data from a phase 1/2 clinical trial, shares of ProQR Therapeutics N.V.(NASDAQ:PRQR), a clinical-stage biotech focused on RNA medicines that treat rare genetic diseases, rose 70% as of 12:13 p.m. EDT on Wednesday. ProQR reported results from its phase 1/2 trial that is testing its compound called QR-110 as a hopeful treatment for LCA10, which is a genetic mutation that usually leads to childhood blindness.
![](https://lifescicommunications.com/wp-content/uploads/2018/04/Reuters-Logo-1-300x98.png)
ProQR soars as childhood blindness drug succeeds in early trial
Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision. The Dutch drug developer said it would now stop enrollments for the small study and progress to a mid-stage trial, which is expected to start in the first half of 2019.
![](https://lifescicommunications.com/wp-content/uploads/2018/09/logo-fox-5-new-york-wnyw.png)
Lyme & Reason: Battles & Breakthroughs Against Lyme Disease
It’s a battle that has been raging for decades – the battle against Lyme Disease. Over the years, progress has been made against this dreaded tick-borne illness. But with breakthroughs come even more barriers. Watch this early peek at a new Fox 5 News special on the fight that could be signaling a new chapter in the ongoing bout against Lyme.
![](https://lifescicommunications.com/wp-content/uploads/2018/09/massdevice_logo_PMS179-300x130.jpg)
Check-Cap touts interim post-CE Mark C-Scan study results
Check-Cap (NSDQ:CHEK) today released interim results from the post-CE Mark approval study of its C-Scan system version 3, touting the device’s ability to detect polyps in un-prepped colons.
![](https://lifescicommunications.com/wp-content/uploads/2018/09/ITN-logo1_bk_Blue_RGB-300x209.jpg)
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an ingestible, capsule-based device for preparation-free colorectal cancer (CRC) screening. The company said data from the multicenter clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon.